New perspectives in the treatment of Melanoma: Anti-angiogenic and anti-lymphangiogenic strategies

Recent Patents on Anti-Cancer Drug Discovery

Volumn 2, Issue 1, 2007, Pages 73-78

  Facchetti, Floriana ^a   Monzani, Elena ^a   La Porta, Caterina A M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Angiogenesis; Lymphagiogenesis; Melanoma

Indexed keywords

ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; DACARBAZINE; INTERLEUKIN 2; LENALIDOMIDE; LYMPHANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY LM 609; SEMAXANIB; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 3;

CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; KAPOSI SARCOMA; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MELANOMA; METASTASIS POTENTIAL; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; REVIEW; SENTINEL LYMPH NODE; SURVIVAL TIME; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHANGIOGENESIS; MELANOMA; PATENTS AS TOPIC;

EID: 34248227037     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489207779561390     Document Type: Review

References (89)

1. de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. In J Cancer 2003; 107: 119-26.
2. MacKie RM, Bray CA, Hole DJ et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002; 360: 587-91.
3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
4. Giles D, Dwyer T, Coates M, et al. Trends in skin cancer in Australia: An overview of the available data. Trans. Menzies Found 1989; 40: 143-47.
5. Morton DL, Essner R, Calch C. Surgical excision of distant metastasis. In: Bach C, Houghton A, Sober A, et al., Editors Cutaneous melanoma 4th ed. St Louis (MO): Quality Medical Publishing, 2003; 547-72.
6. Balch CM, Buzaid AC, Soong S-J, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 2001; 19: 3635-48.
7. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-66.
8. Millward MJ, Bedikian AY, Conry RM, Gore ME, Pehamberger HE, Sterry W, et al. Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bc1-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): analysis of long term survival. Proc Am Soc Clin Oncol 2004; 23:708 (Abstr. 7505).
9. Luikart SD, Kennealey GT, Kirkwood JM. Randomized pase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 1984; 2: 164-68.
10. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-51.
11. Middleton M, Lorigan P, Owen J, et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000; 82: 1158-62.
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
13. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29(6 Suppl 16): 15-18.
14. Mihm MC Jr, Clark WH Jr, Reed RJ. The clinical diagnosis of malignant melanoma. Semin Oncol 1975; 2: 105-18.
15. Warren BA, Shubik P. The growth of the blood supply to melanoma transplants in the hamster cheek pouch. Lab Invest 1966; 15: 464-78.
16. Hubler WR Jr., Wolf JE Jr. Melanoma. Tumor angiogenesis and human neoplasia. Cancer 1976; 38: 187-92.
17. Stenzinger W, Bruggen J, Macher E, Sorg C. Tumor angiogenic activity (TAA) production in vitro and growth in the nude mouse by human malignant melanoma. Eur J Cancer Clin Oncol 1983; 19: 649-56.
18. Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003; 22: 3172-79.
19. Weninger W, Uthman A, Pammer J, et al. Vascular endothelial growth factor production in normal epidermis and in benign and malignant epithelial skin tumors. Lab Invest 1996; 75: 647-57.
20. Hawighorst T, Velasco P, Streit M, et al. Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J 2001; 20:2631-40.
21. Hawighorst T. Angiogenesis, lymphangiogenesis, and tumor progression. Zentralbl Gynakol 2002; 124: 497-05.
22. Detmar M, Hirakawa S. The formation of lymphatic vessels and its importance in the setting of malignancy. J Exp Med 2002; 196: 713-18.
23. Oliver G, Detmar M. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev 2002; 16: 773-83.
24. Jendreyko N, Popkov M, Rader C, Barbas CF 3rd. Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc Natl Acad Sci USA 2005; 102: 8293-98.
25. La Porta, R. Comolli. Different levels of TGFbeta, IL-10, IFNgamma and gelatinase A occur in experimental white and black metastases induced by bryostatin 1 or by phorbol ester-treated BL6T murine melanoma cells. Clin Exp Metastasis 2000; 18: 361-69.
26. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155: 739-52.
27. Hendrix MJ, Seftor RE, Seftor EA, et al. Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination. Cancer Res 2002; 62: 665-68.
28. Seftor RE, Seftor EA, Koshikawa N, et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metallopro-teinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001; 61: 6322-27.
29. Erhard H, Rietveld FJ, van Altena MC, Brocker EB, Ruiter DJ, de Waal RM. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res 1997; Suppl 2:S19-26.
30. Marcoval J, Moreno A, Graells J, et al. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol 1997; 24: 212-18.
31. Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 1997; 76: 930-34.
32. Vlaykova T, Laurila P, Muhonen T, et al. Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. Melanoma Res 1999; 9: 59-68.
33. Reed JA, McNutt NS, Albino AP. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. Am J Pathol 1994; 144: 329-36.
34. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19: 577-83.
35. Eisen T, Boshoff C, Mak I, et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 82: 812-17.
36. D'Amato, R.: US20016235756 (2001).
37. Danson S, Lorigan P, Arance A, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003; 21: 2551-57.
38. Hwu WJ, Krown SE, Menell JH, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Chn Oncol 2003; 21: 3351-56.
39. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87: 1166-72.
40. Bartlett JB, Michael A, Clarke IA, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004; 90: 955-61.
41. Tucker GC. Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 2003; 4: 722-31.
42. Fanslow, W.C., Cerretti, D.P., Poindexter, K.M., Black, R.A.: US20067074408 (2006).
43. Peterson AC, Swiger S, Stadler W, et al. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in patients with advanced melanoma. Proc Am Soc Clin Oncol 2003; 22: 712 (Abstr. 2863).
44. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
45. Carson WE, Biber J, Shah N, et al. A phase 2 trial of a recombinant humanized monoclonal anti-vascular endothelial growth factor (VEGF) antibody in patients with malignant melanoma Proc Am Soc Clin Oncol 2003; 22: 715 (Abstr. 2873).
46. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997; 276: 1423-25.
47. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (FItA). Proc Natl Sci Acad USA 1998; 95: 548-53.
48. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001; 20: 672-82.
49. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192-98.
50. Veikkola T, Jussila L, Makinen T, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001; 20: 1223-31.
51. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-91.
52. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-74.
53. Sleeman JP, Krishnan J, Kirkin V, et al. Markers for the lymphatic endothelium: in search of the holy grail? Microsc Res Tech 2001; 55: 61-69.
54. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995; 92: 3566-70.
55. Kukk E, Lymboussaki A, Taira S, et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996; 122: 3829-37.
56. Oh SJ, Jeltsch MM, Birkenhager R, et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol 1997; 188: 96-109.
57. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the F1t4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15: 290-98.
58. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999; 144: 789-801.
59. Prevo R, Banerji S, Ferguson DJP, Clasper S, Jackson DG. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem 2001; 276: 19420-30.
60. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 2001; 22: 317-21.
61. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999; 98: 769-78.
62. Sosa-Pineda B, Wigle JT, Oliver G. Hepatocyte migration during liver development requires Prox1. Nat Genet 2000; 25: 254-55.
63. Wigle JT, Chowdhury K, Gruss P, Oliver G. Prox1 function is crucial for mouse lens-fibre elongation. Nat Genet 1999; 21: 318-22.
64. Weninger W, Partanen TA, Breiteneder-Geleff S, et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 1999; 79: 243-51.
65. Ebata N, Nodasaka Y, Sawa Y, et al. Desmoplakin as a specific marker of lymphatic vessels. Microvasc Res 2001; 61: 40-48.
66. Wells KE, Rapaport DP, Cruse CW, et al. Sentinel lymph node biopsy in melanoma of the head and neck. Plast Reconstr Surg 1997; 100: 591-94.
67. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276: 1818-22.
68. Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperativc radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996; 223: 217-24.
69. Leak LV. The structure of lymphatic capillaries in lymph formation. Fed Proc 1976; 35: 1863-71.
70. Dadras SS, Detmar M. Angiogenesis and lymphangiogenesis of skin cancers. Hematol Oncol Clin North Am 2004; 18: 1059-70.
71. Tille JC, Nisato R, Pepper MS. Lymphangiogenesis and tumor metastasis. Novartis Found Symp 2004; 256: 112-31.
72. Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001; 61: 1786-90.
73. He Y, Kosaki K, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002; 94: 819-25.
74. Krishnan J, Kirkin V, Steffen A, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res 2003; 63: 713-22.
75. Achen MG, Williams RA, Minekus MP, et al. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumor angiogenesis. J Pathol 2001; 193: 147-54.
76. Dadras SS, Paul T, Bertoncini J, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003; 162: 1951-60.
77. Schneider M, Othman-Hassan K, Christ B, Wilting J. Lymphangioblasts in the avian wing bud. Dev Dyn 1999; 216: 311-19.
78. Salven P, Mustjoki S, Alitalo R, Alitalo K, Raffi S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003; 101: 168-72.
79. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci USA 1998; 95: 258-63.
80. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
81. Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 2001; 93: 1638-43.
82. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-91.
83. Makinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001; 7: 199-205.
84. Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, deVos AM. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 1997; 91: 695-704.
85. Fong AT, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inbibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106.
86. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-89.
87. Skobe M, Brown LF, Tognazzi K, et al. Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and Flt-4 are expressed in AIDS-associated Kaposi's sarcoma. J Invest Dermatol 1999; 113: 1047-53.
88. Marchiò S, Primo L, Pagano M, et al. Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells. J Biol Chem 1999; 274: 27617-22.
89. Skobe M, Brown LF, Tognazzi K, et al. Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and Flt-4 are expressed in AIDS-associated Kaposi's sarcoma. J Invest Dermatol 1999; 113: 1047-53.